Ajinomoto (TSE:2802) Valuation Check After Strong Full Year Earnings And Profit Growth

Ajinomoto (TSE:2802) recently reported full year results to March 31, 2026, with sales of ¥1,583,719 million and net income of ¥134,675 million, alongside higher basic earnings per share versus the prior year. See our latest analysis for Ajinomoto. The stock has been strong over multiple timeframes, with a 22.71% 90 day share price return and a 57.05% 1 year total shareholder return, which aligns with improving earnings and investor confidence in the latest results. If Ajinomoto's move has you looking beyond the food sector, this could be a good moment to broaden your search and uncover 13 top founder-led companies With Ajinomoto trading close to its analyst price target, yet flagged by some metrics as carrying an intrinsic discount, the key question for you is simple: is there still a buying opportunity here, or is the market already pricing in future growth? Most Popular Narrative: 2% Overvalued Ajinomoto's most followed valuation narrative puts fair value at ¥4,932, just below the last close of ¥5,030. This sets up a finely balanced outlook driven by growth and margin expectations. Ongoing investment in R&D and human capital, particularly in Functional Materials and Bio-Pharma Services, is expected to yield differentiated, higher-value products (e.g., specialty amino acids, AI/PC/server-related materials). This is seen as strengthening the competitive moat and gradually improving net margins over the long term. Read the complete narrative. Curious what earnings path and margin shift need to line up for that fair value? The narrative leans on steady revenue progress, firmer profitability, and a premium future earnings multiple that sits well above the wider food sector. Result: Fair Value of ¥4,932 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points to watch, including ongoing raw material cost inflation and persistent volume weakness in markets such as Nigeria and Thailand. Find out about the key risks to this Ajinomoto narrative. Another View: Cash Flows Point To Undervaluation While the popular narrative says Ajinomoto is about 2% overvalued against the analyst fair value of ¥4,932, the SWS DCF model tells a different story. On that view, the stock at ¥5,030 is trading below an estimated future cash flow value of ¥5,359, which suggests a potential valuation cushion rather than stretch. So which lens do you trust more when the signals pull in opposite directions? Before you lean on any single method, it is worth seeing how the SWS DCF model ties cash flow assumptions to that higher fair value and what would need to change for the gap to close or widen, Look into how the SWS DCF model arrives at its fair value. 2802 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ajinomoto for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 15 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals leaves you unsure, it may be a good time to review the numbers yourself and decide where you stand. Start with 3 key rewards. Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that fit your goals even better. Use the screener to quickly surface ideas that match your style. Target potential value with 15 high quality undervalued stocks that combine quality fundamentals with prices the market may not fully reflect. Build a steadier income stream by focusing on companies in 36 dividend fortresses that currently offer higher yields. Prioritise resilience by filtering for businesses in 52 resilient stocks with low risk scores that score well on financial strength and risk metrics. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free